



# Index

(CR) indicates Case Report; (SR) indicates Short Report; (L) indicates Letter to the Editor. Supplements are indicated by S followed by the Supplement letter and the page number.

- $\alpha_1$ -protease inhibitor deficiency: blood gases at rest and during exercise in patients with 1177-1183
- acquired immunodeficiency syndrome and tuberculosis, preferential recruitment of phagocytes into the lung 64-70
- airway obstruction: and chronic exertional dyspnoea in patients with persistent
  - : in relation to symptoms in chronic respiratory disease 356-363
- abdominal surgery, role of spirometric and arterial gas data in predicting pulmonary complications after 1171-1176
- Abe S 155-160, 935-942
- acid fog, naturally occurring, effect on inflammatory mediators in airway and pulmonary functions in asthmatic patients 935-942
- acquired immunodeficiency syndrome and tuberculosis, preferential recruitment of admission for in early childhood 288-294
- adrenaline, inhaled nebulized, improves lung function in infants with acute bronchiolitis 709-714
- Agabiti N 397-403
- Agusti C 345-349
- Ahonen A 1097-1102
- airway hyper-responsiveness: and asthma in adults who required hospital admission for bronchiolitis in early childhood 288-294
- airway obstruction: and chronic exertional dyspnoea in patients with persistent bronchial asthma 694-701
  - : chronic: physiological and symptom determinates of exercise performance 256-263
- airway smooth muscle control: pharmacology of relaxation 519-528
- Akashabi T 87-90
- Akita K 1038-1042
- Al-Bunni A 1053-1056
- Alexander V 82-86
- Allen A 791-799
- Allen J 900-908
- allergy: prevalence of asthma and allergy among university freshmen in Eskisehir, Turkey 536-541
- Alpha One International Registry, history SC1
- alpha<sub>1</sub>-antitrypsin deficiency: epidemiology and prevalence SC7
  - : incidence and detection programme SC18
  - : mechanism SC3
- alpha<sub>1</sub>-antitrypsin null alleles, molecular mechanism SC7
- alpha<sub>1</sub>-Pi deficiency, screening in patients with lung diseases SC16
- Alton M 482-489
- Alvaréz JM 835-840
- Ambrosino M 256-263
- Ambroxol: effect of treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia 378-384
- amiodarone and the lung: wide variations in clinical practice (SR) 1130-1131
- Andersen C 150-154
- Andersson A 607-611
- Andersson B 264-272, 881-887
- Ando M 784-790
- Andrews S SB10-17
- Aneiro L 18-27
- aneurysm, idiopathic, of the pulmonary artery, untreated: long term follow-up (CR) 404-405
- Antczak A 416-421
- Antigen-induced airway inflammation and hyper-responsiveness and airway responses to antigen challenge 44-50
- Antonelli Incalzi R 1079-1084
- apnoea, nocturnal, and desaturation, correlation with lung volume 233-239
- Appelberg J 233-239
- Argaman A 1200-1205
- Aromaa A 356-363
- Arvå E 264-272
- Arvidsson P 574-577
- asthma: and diet 925-934
  - : accuracy of recorded deaths in Denmark over 12 months in 1994/95 373-377
  - : and airway hyper-responsiveness in adults who required hospital admission for bronchiolitis in early childhood 288-294
  - : and anxiety 409-415
  - : arterial and bronchoalveolar lavage fluid endothelin-1 concentration 992-996
  - : beclomethasone dipropionate with CFC and non-CFC propellants using the Easibreathe<sup>®</sup> inhaler in paediatric asthma 57-63
  - : clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma SB42
  - : clinical efficacy and safety of fluticasone propionate 250  $\mu$ g twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma SB29
  - : comparison of HFA-BDP Autohaler<sup>®</sup> with budesonide Turbuhaler<sup>®</sup> in control of patients with mild to moderately severe disease SD27
  - : comparison of high and low dose of inhaled budesonide as an initial treatment in newly detected asthma 678-683
  - : compliance with an oral medication: a pilot study using an electronic monitoring device 852-858

# INDEX

- :correlation between objective measures of airway calibre and clinical symptoms :a systematic review of clinical studies 735-741
- :dyspnoea perception before and after treatment with glucocorticosteroids 161-165
- :early discharge of patients with acute 1234-1240
- :economic impact, with CPOD, on Sweden in 1980 and 1991 247-255
- :effect of hospital asthma nurse appointment on inpatient asthma care 82-86
- :electrophysiology and contractile mediators 328-336
- :eosinophil flux into the airways in patients with exercise-induced asthma 1200-1205
- :equivalence of hydrofluoralkane and chlorofluorocarbon formulations (L) 177
- :equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol 549-555
- :evidence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics SB17
- :fluticasone propionate, nebulized, efficacy compared with oral prednisolone in children with an acute exacerbation of asthma 1206-1214
- :from childhood to adulthood:course and outcome of lung function 466-474
- :from childhood to adulthood:severity, allergies, sensitization, living conditions, gender influence and social consequences 454-465
- : *Helicobacter pylori* sero-prevalence 756-759
- :impact of patient education and self-management on morbidity 279-287
- :improving patient compliance with therapy 2-9
- :inflammatory and structural changes in the airway of patients with SD3
- :influence of anti-inflammatory treatment on timing of lowest and highest peak expiratory flow:influence of anti-inflammatory treatment 385-390
- :inhaled glucocorticosteroids decrease hydrogen peroxide level in expired air condensate in asthmatics 416-421
- :inhaled heparin is effective in exacerbations of (SR) 174-175
- :inhaled nebulized adrenaline improves lung function in infants with acute bronchiolitis 709-714
- :monitoring central and peripheral airway inflammation SD7
- :moxifloxacin vs azithromycin in the treatment of patients with exacerbation of chronic bronchitis 1029-1037
- :nordic consensus report on management 299
- :overview of the clinical efficacy of HFA-BDP SD17
- :patient-assessed measures of health outcome 597-606
- :pet ownership and asthma morbidity (SR) 91-92
- :practical evaluation of exacerbation self-management in children and adolescents 1047-1052
- :premenstrual asthma:is it related to use of aspirin or non-steroidal anti-inflammatory drugs? (SR) 828-829
- :prescribing pattern SBy GPs in six European countries 578-583
- :prevalence of asthma and allergy among university freshmen in Eskisehir, Turkey 536-541
- :psychological issues in the treatment of asthmatic patients 742-749
- :pulmonary function and airway responsiveness to zanamivir 166-173
- :relating inflammatory changes to clinical status SF32
- :relative clinical effectiveness of HFA-BDP and fluticasone propionate SD31
- :relative importance of small airways SD1
- :repeatability of ISAAC video questionnaire and accuracy against clinical diagnosis 397-403
- :reproducibility of early and late asthmatic responses to allergen challenge 441-447
- :salmeterol/fluticasone propionate combination therapy 50/250µg twice daily is more effective than budesonide 800µg twice daily in treating moderate to severe asthma 715-723
- :self-management programme, influence of peak expiratory flow monitoring 760-767
- :specialist nurse education, evaluation following accident and emergency department attendance for acute asthma 900-908
- :targets for inhaled treatment SD13
- :underestimated as a cause of sick leave? 977-984
- :work-related factors in new-onset asthma and in exacerbation of pre-existing asthma 529-535
- aspirin:premenstrual asthma:is it related to use of aspirin or non-steroidal anti-inflammatory drugs? (SR) 828-829
- Autohaler<sup>®</sup>, HFA-BDP, comparison with budesonide Turbuhaler<sup>®</sup> in asthma control of patients with mild to moderately severe asthma SD27
- Ayaz A 432-435
- Ayres JG (L) 181, 925-934, SB42
- azithromycin vs moxifloxacin, short course, in the treatment of patients with acute exacerbation of chronic bronchitis 1029-1037
- Azzan L 684-688
- β-agonist treatment, bronchodilator and rebound bronchoconstriction during regular inhaled 767-771
- β<sub>2</sub>-agonists, long acting:clinical role in COPD SE1
- :effect on airway inflammation in asthmatic patients SF22
- Bacci E 441-447, 1073-1076
- Bagger-sjöbäck D 337-344
- Bake B 38-43, 1119-1122, 1154-1160
- Baker JC 925-934
- Bakke PS 279-287, 1057-1064
- Bakst A 1123-1129
- Baldwin DR (SR) 1002-1003
- Balfour-Lynn IM 106-111
- Ballerin L 997-1001
- Bandoh S 475-481, 875-880
- Banham SW 350-354
- Barber PV 369-372
- Barnacle H 1206-1214
- Barnes NC SF13

- Bartlett CLR 422-427, 954-963  
 Baruzzi G 702-708  
 Barziv Y 190-193  
 Basso S 1079-1084, 1171-1176  
 Bast A 815-820  
 Bateman N 1253  
 Baumgarten CR SB17  
 Baverstock AM (CR) 176  
 Beckett P SF22  
 beclomethasone:equivalence of CFC and non-CFC propellants (L) 177-182  
   :dipropionate with CFC and non-CFC propellants using Easibreathe<sup>®</sup> inhaler 57-63  
   :solution aerosol, equivalent asthma control after dose reduction with HFA-134a 549-555  
 Behnke M 1184-1191  
 Bendayan D 190-193  
 Bende M 1119-1122  
 Bendstrup KE (SR) 174-175  
 Bennett DM 1092-1096  
 Bennett LS 895-899  
 Berar-Yanay N 161-165  
 Berger KI 221-227  
 Berglund L 10-17  
 Bestail JC 589-598  
 Bianchi L 256-263  
 Biber Ç 432-435  
 biopsy:anti-inflammatory profile of inhaled corticosteroids:biopsy studies in asthmatic patients SF16  
   :designing bronchial biopsy studies SF3  
   :use in study of airway inflammation SF1  
   :markers of airway inflammation and remodelling SF9  
 Bird Fancier's Lung and the Christmas tree (CR) 176  
 Bisgaard H 612-621  
 Bjerner L 299, 612-621, SF26  
 Bjørtuft Ø 868-874  
 Blanc PD 529-535  
 Bland JM 900-908  
 Boe J 772-777, 868-874  
 Böhme B 378-384  
 Böhning W 948-953  
 Boijesen M 38-43  
 Bomans PHH 815-820  
 Bonecini-Almeida M da G 64-70  
 Bonfitto P 240-246  
 Bons J SB29  
 Booker C 82-86  
*Bordetella pertussis*, interaction with human respiratory mucus *in vitro* 791-799  
 Boshnakova Tz (CR) 830-831  
 Bothamley GH 648-653  
 Boulet L-P 288-294  
 Bousquet J 612-621, SD1, SF1, SF32  
 Boveri B 742-749  
 Brantly M SC7  
 Bratel T 1221-1228  
 Bratten G 482-489  
 Bredin CP 1092-1096  
 Brisman J 529-535  
 Broendum E 150-154  
 bronchiectasis:elevated levels of macrophage-stimulating protein in induced sputum of patients with 784-790  
 bronchiolitis:asthma and airway hyper-responsiveness in adults who required hospital treatment for in early childhood 288-294  
 bronchiolitis obliterans-organizing pneumonia 702-708  
 bronchodilators used in the treatment of COPD, pharmacology SE6  
 bronchopulmonary dysplasia:effect of Ambroxol treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia 378-384  
 Bruecki WM 364-368  
 budesonide:800µg twice daily salmeterol/fluticasone propionate combination therapy  
   :comparison of high and low dose of inhaled, as an initial treatment in newly detected asthma 678-683  
   :effects compared with fluticasone propionate on the HPA-axis in asthmatic patients 482-489  
   :salmeterol/fluticasone propionate combination therapy 50/250µg twice budesonide Turbuhaler<sup>®</sup> comparison with HFA-BDP Autohaler<sup>®</sup> in control of patients with mild to moderately severe asthma SD27  
 Bugnas B SB29  
 Burioka N 71-75  
 Burke CM SF3, SF13  
 Burney P (SR) 828-829  
 Burt PA 369-372  
 Burzi M 702-708  
 Butler T 578-583  
 Butterfield AK 684-688  
 Bye A 166-173  
 Callejas S SB10-17  
 Campbell EJ SC18  
 Capelli A 436-440  
 Caradonna P 1079-1084  
 carbon dioxide, effective elimination by nasopharyngeal high-frequency ventilation (CR) 1132-1134  
 carbon monoxide diffusing capacity ( $D_LCO$ ) and carbon monoxide transfer coefficient ( $KCO$ ), importance of adjustment for alveolar volume 28-37  
 carbon monoxide transfer, changes over 22 years in middle-aged men 1103-1108  
 Carlsen K-H 709-714, 750-755  
 Carlström K 1221-1228  
 Carone M 256-263  
 Carter M 1253  
 Carter R 350-354  
 Carvalho CE 64-70  
 Casanova F 742-749  
 Cass LMR 166-173  
 Castagna F 742-749  
 cattle TB schemes:control or evaluation:a critical reappraisal 1007-1008  
 Cazzato S 702-708  
 Cazzola M 1109-1118

# INDEX

- CD30, evaluation as a marker for Th2 lymphocytes in bronchoalveolar lavage in interstitial lung diseases 345-349
- cefuroxime axetil, compared with moxifloxacin (BAY 12-8039) in the treatment of acute bacterial sinusitis
- Centanni S 742-749
- Cerutti CG 436-440
- Ceylan E 891-894
- Chan KN 756-759
- Chapman KR 2-9
- Chege JK 51-56
- Chikumi H 71-75
- Chin NK 1234-1240
- Chodosh S 18-27
- Choi S 895-899
- chronic alveolar hyperventilation, ventilatory response to CO<sub>2</sub> rebreathing before and after Nocturnal Nasal Intermittent Positive Pressure Ventilation in patients with 1154-1160
- chronic obstructive pulmonary disease:chronic bronchitis and emphysema 204-213
- :circulating levels of soluble Fas ligand and soluble Fas in patients with 1215-1220
  - :clinical role of long acting  $\beta_2$ -agonists SE1
  - :correlates of osteoporosis in 1079-1084
  - :direct medical cost in the USA 1123-1129
  - :economic impact, with asthma, on Sweden in 1980 and 1991 247-255
  - :effectiveness of Visual Analogue Scale 8 in measuring health-related quality of life 1192-1199
  - :health-related quality of life is associated with arterial Po<sub>2</sub> 772-777
  - :home-based exercise is capable of preserving hospital-based improvements 1184-1191
  - :impact of hypoxaemia on neuroendocrine function and catecholamine secretion in, effects of long-term oxygen treatment 1221-1228
  - :impact of patient education and self-management on morbidity 279-287
  - :is it possible to predict the success of non-invasive positive pressure ventilation in acute respiratory failure due to 997-1001
  - :neither IL-1 $\beta$ , IL-1 receptor antagonist, nor TNF- $\alpha$  are associated with susceptibility 847-851
  - :pharmacology of bronchodilators used in the treatment of SE6
  - :randomized controlled trial of ambulatory oxygen and an ambulatory ventilator on endurance exercise 778-783
  - :rehabilitation 150-154
  - :stages of disease severity and factors that affect the health status of patients 841-846
  - :tissue depleted and health related quality of life in patients 859-867
- chronic respiratory disease, airway obstruction in relation to symptoms 356-363
- Chrystyn H (L) 177, 501-504, 51-56
- Chung KF 852-858
- Church D 18-27, 97-105, 1029-1037
- Ciappi G 1079-1084
- cigarette smoke, bronchial reactivity to 119
- Cisternino L 1171-1176
- Clough JB 391-396, 641-644
- Culey S 2-9
- CO<sub>2</sub> rebreathing, ventilatory response before and after Nocturnal Nasal Intermittent Positive Pressure Ventilation in patients with chronic alveolar hyperventilation 1154-1160
- cockroaches and pets:two increasing causes of respiratory allergy in indoor environments:characteristics of airways sensitization and prevention strategies 1109-1118
- cold air provocation, nasobronchial relationship after 1119-1122
- colomycin:ten year review 632-640
- comparative study designs and what they show SD40
- Conti I 441-447
- continuous positive airway pressure therapy, nasal, for obstructive sleep apnoea; efficacy of heated and non-heated humidifiers 364-368
- continuous positive airway pressure:characteristics of patients unable to tolerate 145-149
- Conway SP 632-640
- Corbo GM 397-403
- correlates of osteoporosis in chronic obstructive pulmonary disease 1079-1084
- corticosteroids:and the hypothalamic-pituitary and adrenal axis:do we understand their interaction? 627-631
- :inhaled, anti-inflammatory profile combined with salmeterol in asthmatic patients SF26
  - :inhaled, anti-inflammatory profile:biopsy studies in asthmatic patients SF16
- Couderc LJ 1010
- Cowan JO 767-771
- Cox G (SR) 1130-1131
- Cripps A SB3-7
- Crompton GK (SR) 91-92, 448-453, 496-500
- cystic fibrosis:children, production of growth-related protein  $\alpha$  106-111
- :deaths during pregnancy:three out of four patients were colonised with *Burkholderia cepacia* (CR) 1004-1006
  - :experience of totally implantable venous access devices in adults over a 13-year period 1161-1164
  - :fungal atopy in adult 1092-1096
  - :lung function changes in relation to menstrual cycle in females with 1043-1047
  - :questionnaire survey of male infertility (SR) 1002-1003
- cytokeratin 19 fragments in bronchiolar lavage fluid from patients with idiopathic pulmonary fibrosis 155-160
- D'Amato G 1109-1118
- D'Amato M 1109-1118
- Dahl R 10-17, 119-127, 299, SF22
- Daley-Yates PT SB10-17
- Davidovich A 161-165
- Davies RJO 895-899
- de la Calzada M<sup>a</sup>D 971-976
- de la Hoz RE 221-227
- De Pergola G 240-246
- De Rosa M 397-403
- De Vries J 273-278

- DeAbate CA 18-27, 1029-1037  
Dekhuijzen PNR 627-631  
del CastilloArévalo 760-766  
Dellborg C 135-138, 1154-1160  
Dente FL 441-447, 1073-1076  
Descals C 971-976  
Deschesnes F 288-294  
Desgranges CI 1010  
Devine EB 294-213  
Dewar A 791-799  
Dewar MH 448-453  
Di Cosmo V 1171-1176  
Di Franco A 441-447, 1073-1076  
Di Marco F 742-749  
Di Napoli A 1171-1176  
diabetes mellitus, technetium <sup>99m</sup>Tc-DTPA clearance in the evaluation of pulmonary involvement in patients with 1053-1056  
Dinwiddie R 632-640  
Diskus<sup>®</sup> and Turbuhaler<sup>®</sup>, equivalent therapeutic ratio salbutamol given by 574-577  
Dobashi KO 584-588, 875-880  
Doherty C 900-908  
Dohmoto K 475-481  
Donner CF 436-440  
Dorow P SB17  
Dougan G 791-799  
Drca N 985-991  
Drent M 273-278, 815-820  
Duncan-Skingle F 632-640  
Duranti R 694-701  
dysphonia:comparison of Pulmicort<sup>®</sup> pMDI plus Nebuhaler<sup>®</sup> and Pulmicort<sup>®</sup> Turbuhaler<sup>®</sup> in asthmatic patients with 448-453  
Easibreathe<sup>®</sup> inhaler 57-63  
Easyhaler<sup>®</sup>:efficacy of salbutamol unaffected by low inspiratory flow 1229-1233  
:salbutamol via, is at least as effective as salbutamol via Turbuhaler<sup>®</sup> in the treatment of histamine-induced bronchoconstriction 1097-1102  
Edwards AM (L) 918  
Ehnhage A 1065-1072  
Ehrstedt C 985-991  
Ekberg-Jansson A 38-43, 264-272  
Eklund A 806-814  
Eklund L 139-144  
Elborn JS 632-640  
Elgazzar A 1053-1056  
Elvindson A 482-489  
emphysematous lesions and lung function in healthy smokers 60 years of age 38-43  
endobronchial metastases, treatment with intraluminal radiotherapy 369-372  
Engh G 750-755  
Englert N 194-204  
eosinophil flux into the airways in patients with exercise-induced asthma 1200-1205  
Erdogan Y 432-435  
Ergün P 432-435  
Erikssen J 772-777  
erthromycin inhibits  $\beta_2$ -integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils 654-660  
Evano-Celli I SB29  
Ewig S 556-563  
exercise testing, use of transcutaneous oxygen and carbon dioxide tensions for assessing indices of gas exchange during 350-354  
Exercise-induced bronchoconstriction depends on exercise load 750-755  
Fabbri L 2-9  
Fabbri LM 612-621  
Fairfax AJ SD31  
Fakes DW (L) 179, 181  
Falcone F 702-708  
Falguera M 505-510  
Farmer IS 57-63  
Farr BM 422-427, 954-963  
Fas, soluble and Fas ligand, soluble, circulating levels of in patients with chronic obstructive pulmonary disease 1215-1220  
Faurschou P SF26  
fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma 948-953  
Ficker JH 364-368  
Filella X 345-349  
Filippelli M 694-701  
Fireman E 1200-1205  
Flannery EM 767-771  
flow-volume curve measurements, inter-laboratory comparison as quality control procedure in the framework of an epidemiological study 194-204  
fluticasone propionate:dose proportionality from hydrofluoralkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs SB10-17  
:clinical efficacy and safety of 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma SB42  
:clinical efficacy and safety of 250  $\mu$ g twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma SB29  
:dose proportionality from hydrofluoralkane pressurized metered dose inhalers  
:(pMDIs) and comparability with chlorofluorocarbon pMDIs SB10-17  
:effects compared with budesonide on the HPA-axis in asthmatic patients 482-489  
:nebulized, efficacy compared with oral prednisolone in children with an acute exacerbation of asthma 1206-1214  
:relative clinical effectiveness of HFA-BDP and, in asthma SD31  
:effect on bronchial hyper-responsiveness compared with zafirlukast 112-118  
Foglio K 256-263  
Forbes L (SR) 828-829



# INDEX

- Foreman CT 641-644
- Forestiere F 397-403
- Forli L 868-874
- formoterol:given by Turbuhaler<sup>®</sup> (Oxis<sup>®</sup>) showed as rapid onset of action as salbutamol given by a pMDI 607-611
- via Turbuhaler<sup>®</sup> gave better protection than terbutaline against repeated exercise challenge 661-667
- Forsberg S 1065-1072
- Foschino Barbaro MP 128-134, 240-246
- Franklin KA 569-572
- Freund E 948-953
- Friedman-Jiménez G 221-227
- Fuchs FS 364-368
- Fujita J 475-481, 875-880
- Fukuchu Y 847-851
- Fukunaga Y 875-880
- Fuso L 397-403, 1079-1084, 1171-1176
- Gallefosse F 279-287, 1057-1064
- Gamble E 983-984
- Ganderton D (L) 919
- Garbe BR (L) 917
- Garratt AM 597-606
- Garrod R 589-598
- Gebhardt R SB17
- Geddes DM 1161-1164, (CR) 1004-1006
- Gehanno P 337-344
- Georgiev Ch (CR) 830-831
- Giannini D 1073-1076
- Giannini D 441-447
- Gigliotti D 806-814
- Gilliland WR 228-232
- Giorgino R 240-246
- glucocorticosteroids, effect on dyspnoea perception in asthma 161-165
- glucocorticosteroids, inhaled, decrease hydrogen peroxide level in expired air condensate in asthmatics 416-421
- Gnemmi I 436-440
- Göke N 556-563
- Goldberg J 948-953
- Goldring RM 221-227
- Gonzalez FJ 835-840
- Goris A 859-867
- Goulet R 288-294
- Grammer LC 964-970
- Greening A 612-621
- Greening AP (SR) 91-92
- Gregory D 578-583
- Greif J 1200-1205
- Grönnéröd TA 661-667
- growth-related protein  $\alpha$ , production in cystic fibrosis children 106-111
- Grunewald J 806-814
- Grzelewska-Rzymowska I 800-805
- Gude F 835-840
- Guemas E 490-495
- Guido P 128-134
- Gunawardena KA 166-173
- Gustafsson PM 454-465, 466-474
- Gyllenhammar H 1065-1072
- Haahtela T 612-621
- Hahn EG 364-368
- Hajiro T 841-846
- Haluszka J 194-204
- Hamnegård C-H 1154-1160
- Hampel B 337-344
- Hancox M 1007-1008, (L) 920
- Hancox RJ 767-771
- Hara H 385-390
- Harlid R 135-138
- Harputluoglu Y 432-435
- Harsch IA 364-368
- Hasegawa S 542-548
- Hashimoto S 385-390
- Hautmann H 689-693
- Haverstock D 18-27, 97-105
- Hawsworth GM 501-504
- Heinrich J 668-677
- Helenius H 909-916
- Helicobacter pylori* sero-prevalence in asthma 756-759
- Hemmingsen L 150-154
- Henry M 1092-1096
- heparin, inhaled, effectiveness in exacerbations of asthma (SR) 174-175
- Herbison GP 767-771
- Herdman MJ 57-63
- Hertzman P 247-255
- Heyd A 1029-1037
- HFA-BDP:and its implications for the quiet zone SD37
- :Autohaler<sup>®</sup> comparison with budesonide Turbuhaler<sup>®</sup> in control of patients with mild to moderately severe asthma SD27
- :an overview of clinical efficacy in asthma SD17
- :relative clinical effectiveness, and fluticasone propionate in asthma SD31
- Hino T 155-160
- Hiroi M 875-880
- Hisada T 584-588
- histamine-induced bronchoconstriction, salbutamol via Easyhaler<sup>®</sup> is at least as effective as salbutamol via Turbuhaler<sup>®</sup> in the treatment of 1097-1102
- Hnatiuk OW 228-232
- Ho JC 943-945
- Ho JL 64-70
- Hodgkin's disease, primary pulmonary:report of two cases (CR) 830-831
- Hodson ME 1161-1164, (CR) 1004-1006
- Hoffman HJ 10-17
- Hoffmann G 76-81
- Högman M 985-991
- Hoiby N 632-640
- Hojo S 475-481
- Holgate ST 391-396, 612-621, SD3
- Holz O SD7
- Honeybourne D 684-688
- Honma S 935-942

- Honour JW 627-631  
Horie T 87-90  
Horio H 214-220  
Hosoi T 847-851  
Howarth PH SF22  
Hu W 756-759  
Hughes S 1206-1214  
human neutrophil lipocalin and myeloperoxidase: studies of lung lavage fluid and lung tissue 564-568  
Hutchinson A 597-606  
hydrogen peroxide generation compared with the content of lipid peroxidation products in lung cancer tissue and pulmonary parenchyma 800-805  
hypercapnia, diurnal, in morbidly obese subjects with obstructive sleep apnoea 240-246  
hypoxaemia, impact on neuroendocrine function and catecholamine secretion in COPD, effects of long-term oxygen treatment 1221-1228
- Iacono P 490-495  
Ibanez JM 337-344  
Igarashi T 935-942  
Iizuka K 584-588  
Ikeda A 841-846  
immune function, regulated exocytosis, involvement of SNARE proteins 10-17  
Impivaara O 356-363  
Inage M 155-160  
inhaler use, inappropriate: assessment of use and patient preference of seven inhalation devices 496-500  
inhalers, non-CFC pressurized metered dose, pharmaceutical transition to SB3-7  
inhalers: dose proportionality of fluticasone propionate from hydrofluoralkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs SB10-17  
Innes JA 496-500  
Inoue M 542-548  
Inoue S 1215-1220  
Interleukin-13 mRNA expression, increased, in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations 806-814  
ipratropium bromide, improved delivery using Respimat<sup>®</sup> compared with a conventional metered dose inhaler 490-495  
Irrjala K 909-916  
Ishida T 875-880  
Ishii T 847-851  
Ishizuka T 584-588  
Ito D 87-90  
Iwamae S 584-588  
Iwasaki Y 385-390
- Jackson A 791-799  
Jackson CM (L) 177  
Jacobsen E 135-138  
Jacobsen L 247-255  
James L 501-504  
James MH 715-723
- Jamieson AH 448-453  
Jann E 76-81  
Janson C 145-149, 233-239, 1043-1046  
Jarjour NN SF3  
Jarvis D 1253, (SR) 828-829  
Javitz HS 1123-1129  
Jeffery PK SF9  
Jenkins C 715-723, 724-732  
Jensen EJ 119-127  
Jensen JI (SR) 174-175  
Jepson G 578-583  
Johannesson M 1043-1046  
Johansson A 1119-1122  
Johnson DC 28-37  
Johnson J (SR) 1130-1131  
Johnston IDA (SR) 1130-1131  
Jones K 578-583  
Jones PW 256-263, 589-598  
Jörres RA 668-677, 1184-1191, SD7  
Joyce H 1103-1108  
Juto J-E 1065-1072
- Kamel T 475-481  
Kariyawasam HH 1161-1164  
Kasielski M 416-421  
Kato S 155-160  
Kava T 983-984, 1215-1220  
Kawaguchi H 1038-1042  
Keig P 791-799  
Kelleher N 1092-1096  
Kerkhofs M 76-81  
Keski-karhu J 1097-1102, 1229-1233  
Kettner J SB17  
Keyf AI 432-435  
Kiely J 1092-1096  
Kilinc O 891-894  
Kinnear WJM (SR) 1130-1131  
Kips J SE1  
Kirsten D 1184-1191  
Kiter G 891-894  
Kivity S 1200-1205  
Kjaersgaard P 482-489  
Kjellman B 454-465, 466-474  
Kleinfeld T 556-563  
Klugh TT 221-227  
Knox AJ (SR) 1002-1003  
Kock C 632-640  
Kofstad J 868-874  
Kölbeck K-G 1065-1072  
Kolsuz M 536-541  
Konietzko N 1177-1183  
Kosaka N 87-90  
Koskela T 1229-1233  
Koss M (CR) 830-831  
Kramer MR 190-193, 1154-1153  
Kritski AL 64-70  
Kubota Y 385-390  
Kunka R SB10-17  
Kuo H-P 654-660

# INDEX

- Kurmanowska Z 416-421  
 Kwiatkowska S 800-805  
 Kwok E 756-759
- Laberge S 44-50  
 Lähelmä S 1097-1102  
 Laitinen A SF9  
 Lam B 943-945  
 Lam SK 756-759  
 Lam WK 756-759, 943-945  
 Lambert PA 632-640  
 Lamers RJS 815-820  
 Lamorgese V 128-134  
 Lange P 150-154, 373-377  
 Larouche V 288-294  
 Larsson K 139-144, 821-827, 1065-1072  
 Larsson PH 821-827  
 Larsson S 881-887  
 Leclerc V 490-495  
 Lee JH SC7  
 Lee KH 1234-1240  
 Leff J 612-621  
 Legari G 240-246  
 Legendre M SB29  
 Lehnigk B 1184-1191  
 Lenney J 496-500  
 Lenney W 1206-1214  
 Lensmar C 806-814  
 Levy G 971-976  
 Levy ML 900-908  
 Liccardi G 1109-1118  
 Lim TK 1234-1240  
 Lin H-C 654-660  
 Lindberg E 145-149  
 Lindren B 247-255  
 Linkowski P 76-81  
 Lion Intoxilyzer<sup>®</sup> 6000 breath alcohol testing device, a study to investigate the ability of subjects with chronic lung disease to provide evidential breath samples using 684-688  
 Lipworth BJ SD13, (L) 177  
 Littlewood JM 632-640  
 Liu C-Y 654-660  
 Lloberes P 971-976  
 Lødrup Carlsen KC 709-714  
 Löfdahl CG 38-43, 247-255, 264-272  
 Lomas DA SC3  
 London Chest Activity of Daily Living scale:development and validation 589-598  
 loop-sheet polymerization:the mechanism of  $\alpha_1$ -antitrypsin deficiency SC3  
 López-Viña A 760-766  
 Lötvall J 574-577, SE6  
 Loubani M 888-890  
 Low JL 391-396  
 lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations 881-887  
 Luburich P 345-349
- Lucas JS 641-644  
 Lúdvíksdóttir D 1043-1046  
 Luisetti M SC1  
 Lundbäck B 482-489, 715-723, 724-732, 977-984  
 lung cancer:patients, assisted pressure control ventilation via a mini-tracheostomy tube for postoperative respiratory management of 214-220  
   :serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with 1085-1091  
   :tissue and pulmonary parenchyma:hydrogen peroxide generation compared with the content of lipid peroxidation products in 800-805  
 lung deposition of inhaled medications (L) 918, 919  
 lung function in infancy, measuring 641-644  
 lung volume and its correlation to nocturnal apnoea and desaturation 233-239  
 Lusuardi M 436-440  
 Lybeck K 150-154  
 lymphocyte surface antigens, expression in bronchial biopsies, bronchoalveolar lavage cells and blood cells in healthy smoking and never-smoking men 264-272  
 lymphoepithelioma-like carcinoma of the lung, chemoradiotherapy for 943-945  
 Lynch V 888-890
- Macchionii P 441-447  
 Madsen F 373-377, (E) 187-189, (L) 917  
 Maeda H 1038-1042  
 Magadle R 161-165  
 Magnussen H 549-555, 668-677, 1184-1191, SD7  
 Majander R 678-683  
 Mäkiä E 356-363  
 Malmberg P 139-144, 977-984  
 Malmström K 1229-1233  
 Man A 1200-1205  
 Manjra AI 1206-1214  
 Manuel Porcel J 505-510  
 Marangos M 992-996  
 Markewitz BA 1023-1028  
 Martin JG 44-50  
 Maskell D 791-799  
 Mathew CP 1029-1037  
 Matot I 1154-1153  
 Matsui 847-851  
 Matsuse T 847-851  
 Matusiewicz SP 448-453, (SR) 91-92  
 McCowan C 82-86  
 McCracken JS 422-427  
 Macfarlane JT 422-427  
 McLachlan CR 767-771  
 McLean A 448-453  
 MacMahon MM 166-173  
 mechanical ventilation, home, in Sweden 135-138  
 Mellén A 574-577  
 membrane humidifier, evaluation of one not requiring water 71-75  
 Mercham S 1253  
 Meriläinen P 985-991  
 Metintas S 536-541



- Michael JR 1023-1028  
 Michailova V (CR) 830-831  
 Middle M 57-63  
 Midgren B 135-138  
 Milanowski J (L) 183  
 Millar AB SB 42  
 Miller DL 422-427, 954-963  
 Millqvist E 1119-1122  
 Minai OA (CR) 1241-1251  
 Minenna A 240-246  
 Miravities M SC7  
 Miyao M 847-851  
 Miyawaki H 475-481  
 Mohamed M 1053-1056  
 Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomised, double-blind comparative study 612-621  
 Moore AJ 684-688  
 more effective than budesonide 800 $\mu$ g twice daily in treating moderate to severe  
 Morgan MDL 778-783  
 Mori M 584-588  
 Mørk M 750-755  
 Mostert R 859-867  
 Mousa K 1053-1056  
 moxifloxacin: (BAY 12-8039), compared with cefuroxime axetil in the treatment of acute bacterial sinusitis 337-343  
 : efficacy and safety in treatment of pneumonia 97-105  
 : therapy, short-course, for treatment of acute bacterial exacerbations of chronic bronchitis 18-27  
 : vs azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis 1029-1037  
 Muilol J 428-431  
 Muir J-F SD17  
 Mukhopadhyay S 82-86  
 Müller-Suur C 821-827  
 Mullins R 895-899  
 Munch EP 373-377  
 Murphy FT 228-232  
 Mustafa HT 1053-1056  
 Myaue H 875-880  
 myeloperoxidase and human neutrophil lipocalin: studies of lung lavage fluid and lung tissue 564-568  
 Nabilla A 1053-1056  
 Nakagawa M 385-390  
 Nakamura H 155-160, 1215-1220  
 nasal continuous airway pressure: in obstructive sleep apnoea: which derivative from overnight oximetry best predicts symptomatic response to? 895-899  
 nasal continuous positive airway pressure, effects on daytime sleepiness in patients with obstructive sleep apnoea 87-90  
 Nathell L 977-984  
 Naya I 852-858  
 nebulisers, salt output 139-144  
 nedocromil sodium, inhibition of GM-CSF secretion by topical corticosteroids and 428-431  
 Nielsen D 150-154  
 Nielsen LP 10-17  
 Nielsen S 10-17  
 Niemann-Pick disease: pulmonary involvement: case report and literature review (CR) 1241-1251  
 Niepsuj G 194-204  
 Nikolaidis P 337-344  
 Nilmi T 1038-1042  
 Nilsson O 264-272  
 Ning ACWS 448-453  
 Ninomiya H 542-548  
 Nishimura K 841-846  
 nitric oxide: a demand valve device decreases exhaust nitric oxide and nitrogen dioxide by nitric oxide inhalation with a nasal cannula 542-548  
 : exhaled, partitioned into alveolar, lower airways and nasal contributions 985-991  
 : inhaled, in adults with the acute respiratory distress syndrome 1023-1028  
 Nocturnal Nasal Intermittent Positive Pressure Ventilation, ventilatory response to CO<sub>2</sub> rebreathing before and after in patients with chronic alveolar hyperventilation 1154-1160  
 Nöges E 145-149  
 Nogués A 505-510  
 Nomori H 214-220  
 Nordahl G 233-239  
 Nørregaard O 135-138  
 Nosedá A 76-81  
 Nowak D 416-421, 800-805  
 Nusko G 364-368  
 Nygren A 977-984  
 obstructive sleep apnoea: diurnal hypercapnia in morbidly obese subjects with 240-246  
 : efficacy of heated and non-heated humidifiers during nCPAP-therapy 364-368  
 : self-reported sleepiness while driving as a risk factor for traffic accidents 971-976  
 : which derivative from overnight oximetry best predicts symptomatic response to nasal continuous airway pressure? 895-899  
 Oga T 841-846  
 Ogston S 82-86  
 Ohtsu I 542-548  
 Ohtsuki Y 875-880  
 Okada H 475-481  
 Olin A-C 529-535  
 Olofson J 1154-1160  
 Olofson J 135-138  
 Omar A 1053-1056  
 Onadeko BO 1053-1056  
 Onishi S 875-880  
 Onn A 1200-1205  
 Ooi GC 943-945  
 Oshikawa K 1085-1091  
 osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms 228-239  
 Östling-kulting E 1097-1102  
 Ottanelli R 694-701

# INDEX

- Ouchi Y 847-851  
 ovine TB alert (L) 920  
 Oxis<sup>®</sup> (formoterol given by Turbuhaler<sup>®</sup>) showed as rapid  
   an onset of action as salbutamol given by a pMDI 607-  
   611  
 oxygen therapy, administering, monitoring and withdraw-  
   ing (L) 1253  
 Özdemir N 536-541
- Pacini F 694-701  
 Pagani M 256-263  
 Pagano F 1079-1084  
 Paggiaro PL 441-447, 1073-1076  
 Palmberg L 1065-1072  
 Palmqvist M 574-577  
 Panella GL 997-1001  
 Partridge MR 983-984  
 Pasma HR 112-118  
 Patel T 97-105  
 patient satisfaction with healthcare in asthmatics and  
   patients with COPD before and after patient education  
   1057-1064  
 Paul EA 589-598  
 Pavord ID (L) 182  
 Pearl J 97-105  
 Pedersen JI 868-874  
 Pedersen S SD40  
 Peltola S 1229-1233  
 Pepper JR 1161-1164  
 Perrin VL 57-63, (L) 179, 181, 183  
 pet ownership and asthma morbidity (SR) 91-92  
 Petermann F 409-415  
 Petkova D 345-349  
 pets and cockroaches:two increasing causes of respiratory  
   allergy in indoor  
   environments:characteristics of airways sensitization and  
   prevention strategies 1109-1118  
 Piascka G 800-805  
 Piattella M 997-1001  
 Piazzini A 742-749  
 Picado C 345-349, 428-431, 612-621  
 Picca V 128-134  
 Pimazzoni M SB10-17  
 Pistelli F 194-204  
 Pistelli R 397-403, 1079-1084, 1171-1176  
 pleural fluid C-reactive protein in diagnosis of pleural  
   effusions 432-435  
 pneumonia:risk factors for community-acquired pneumo-  
   nia diagnosed by GPs in the community 422-427  
   :treatment with moxifloxacin 97-105  
 pneumonia, community acquired:development of a bedside  
   predictive model and scoring system to identify the  
   aetiology 505-510  
   :management of patients in a primary care hospital 556-  
   563  
   :risk factors for, diagnosed upon admission 954-963  
 pneumothorax, spontaneous:video assisted thoracoscopic  
   bullectomy and acromycin pleurodesis 888-890  
 Poletti V 702-708
- pollen:natural exposure to pollen reduces the threshold but  
   does not change the pattern of response to the allergen in  
   allergic subjects 1073-1076  
 Polo O 909-916  
 Polo-Kantola 909-916  
 Popov D SB22  
 positive pressure ventilation, non-invasive:is it possible to  
   predict the success of in acute respiratory failure due to  
   chronic obstructive pulmonary disease 997-1001  
 Postmus PE 404-405  
 Potena A 997-1001  
 Poulter LW SF3, SF13  
 Poussa T 678-683  
 prednisolone, oral, efficacy compared with nebulized  
   fluticasone propionate in children with an acute exacer-  
   bation of asthma 1206-1214  
 premenstrual asthma:is it related to use of aspirin or non-  
   steroidal anti-inflammatory drugs? (SR) 828-829  
 pressure monitor, nasal continuous positive airway pressure  
   assessed with, influence of sleep habits 76-81  
 Price J 1206-1214  
 Price JF 106-111  
 Price MJ 724-732  
 Pride NB 1103-1108  
 Prieto, J 806-814  
 progestin, short-term, IGF-1 and ventilation after, in  
   postmenopausal women with chronic respiratory insuffi-  
   ciency 909-916  
 Prud'Homme A SB29  
 Pulmicort<sup>®</sup>:comparison of Pulmicort<sup>®</sup> pMDI plus Neb-  
   uhaler<sup>®</sup> and Pulmicort<sup>®</sup>  
   Turbuhaler<sup>®</sup> in asthmatic patients with dysphonia 448-  
   453  
 pulmonary calcifications 190-193  
 pulmonary fibrosis:circulating bronchoepithelial cells ex-  
   pressing mRNA for surfactant protein A in 475-481  
   :idiopathic 155-160  
   :idiopathic:assessing health and quality of life 273-278  
   :idiopathic:serum anti-p53 autoantibodies from patients  
   with associated with lung cancer 1085-1091  
   :in association with human T cell lymphotropic virus  
   type 1 (L) 1010  
 pulmonary sarcoidosis and musculoskeletal symptoms,  
   osseous disease in patients with 228-239  
 Puolijoki H 678-683  
 Putinati S 997-1001  
 Pyke SD SF3
- Quality of Life Questionnaires for respiratory diseases (E)  
   187-189  
 Quantrill SJ 369-372  
 Qvarfordt I 881-887
- radiation pneumonitis, bilateral, caused by unilateral  
   thoracic irradiation, role of anti-epithelial cell antibodies  
   in pathogenesis 875-880  
 Raherison C 1047-1052  
 Rain B 1010  
 Rak S 482-489

- Ranieri P 1079-1084  
 Ratta L 702-708  
 Respimat<sup>®</sup>, improved delivery of ipratropium bromide compared with a conventional metered dose inhaler 490-495  
 Resta O 128-134, 240-246  
 Reunanen A 356-363  
 Revill SM 778-783  
 Richter K 668-677  
 Riebe M SB3-7  
 Riise GC 881-887  
 Ringbaek TJ 150-154  
 Ringdal N 482-489  
 Rivard G 288-294  
 Rivera M 835-840  
 Robb M 900-908  
 Roca A 971-976  
 Roca-Ferrer J 428-431  
 Rodgers HC (SR) 1002-1003  
 Rodriguez JR 835-840  
 Rodriguez-Roisin R 345-349  
 Roemer W 194-204  
 Romagnoli I 694-701  
 Roquet A 806-814  
 Rosi E 694-701  
 Rossi A 702-708  
 Rossi P 44-50  
 Rubio-Caballero M 505-510  
 Ruiz-González A 505-510  
 Russell I 597-606
- Saarelainen P 715-723  
 Saaresranta, T 909-916  
 Sagales T 971-976  
 Sairnen U 1229-1233  
 Saito H 155-160  
 Saito T 542-548  
 Sakamoto O 784-790  
 Sako T 71-75  
 Salat D SB22  
 salbutamol: given by a pMDI, Oxis<sup>®</sup> (formoterol given by Turbuhaler<sup>®</sup>) showed as rapid an onset of action as 607-611  
 : bioavailability to lung using urinary excretion following inhalation 51-56  
 : efficacy via Easyhaler<sup>®</sup> unaffected by low inspiratory flow 1229-1233  
 : equivalence of salbutamol 200  $\mu$ g four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics SB22  
 : evidence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics SB17  
 : given by Turbuhaler<sup>®</sup> and Diskus<sup>®</sup>, equivalent therapeutic ratio 574-577  
 : Montelukast combined with an inhaled steroid in adult asthma: design and rationale of a randomised, double-blind comparative study 612-621  
 : via Easyhaler<sup>®</sup> is at least as effective as salbutamol via Turbuhaler<sup>®</sup> in the treatment of histamine-induced bronchoconstriction 1097-1102  
 salmeterol: anti-inflammatory profile of inhaled corticosteroids combined with, in asthmatic patients SF26  
 salmeterol/fluticasone propionate combination therapy: 50/250  $\mu$ g twice daily is more effective than budesonide 800  $\mu$ g twice daily in treating moderate to severe asthma 715-723  
 : 50/250  $\mu$ g twice daily and budesonide 800  $\mu$ g twice daily in treating asthma, cost-effectiveness 724-732  
 Salonen R 194-204  
 salt output of nebulisers 139-144  
 Sampol G 971-976  
 Sampson AP 106-111  
 San Sebastian M 648-653  
 Sanderson R 448-453  
 Sandström T SF26  
 Sarbinova M (CR) 830-831  
 sarcoidlike granulomas, association of man-made mineral fibre exposure and 815-820  
 sarcoidosis patients, lack of association with interleukin 1 receptor antagonist and interleukin-1 $\beta$  gene polymorphisms 1038-1042  
 Sasaki T 71-75  
 Sato S 1038-1042  
 Savic J 57-63  
 Scano G 694-701  
 Schäfer H 556-563  
 Schiattone ML 702-708  
 Schleimer RP SF13  
 Schmalisch G 378-384  
 Schmekel B 564-568  
 Schmidt P 948-953  
 Schols AMWJ 859-867  
 Schramel FMNH 404-405  
 Schulze M SB3-7  
 Schwabe G 661-667  
 Scottish national bronchoscopy audit: a prospective multi-centre study of 3316 cases against agreed standards 511-515  
 Scuotri L 441-447  
 Seberová E 607-611  
 sedation in outpatient bronchoscopy 1145-1153  
 Seebregts A 273-278  
 Seifert K 556-563  
 serum amino acids in relation to nutritional status, lung function and energy intake in patients with advanced pulmonary disease 868-874  
 Seveus L 564-568  
 Shaughnessy MA 964-970  
 Shimizu Y 584-588  
 Shorr AF 228-232  
 Shukla A 10-17  
 Shwartz Y 1200-1205  
 Sidenius KE 373-377  
 Siegert R 337-344  
 Silvasti M 1097-1102, 1229-1233  
 Simoni M 194-204  
 Simpson AJ (SR) 91-92

# INDEX

- Singh SJ 778-783  
 Skoogh BE 247-255, 1154-1160  
 sleep apnoea: effects of nasal continuous positive airway pressure on daytime sleepiness 87-90  
   : recordings, accuracy of subjective sleep time 569-572  
 sleep habits: compliance with nasal continuous positive airway pressure assessed with pressure monitor 76-81  
 sleep-related breathing disorders in acute respiratory failure assisted by non-invasive ventilatory treatment 128-134  
 Smith E 82-86  
 Smith WM 1123-1129  
 smokers: lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations 881-887  
 smoking cessation advice, availability from health professionals: a census from one East London district 983-984  
 smoking habits in a cohort of UK adolescents 391-396  
 Snell NJC (L) 919  
 snorers, airway disorders and pulmonary function in: a population-based study 835-840  
 So K 204-213  
 Soane MC 791-799  
 Soes-Petersen U 373-377  
 Soliman S 661-667  
 Sommerauer B 337-344  
 Spadaro S 1171-1176  
 Spiropoulos K 992-996  
 Squassante L SB10-17  
 Ståhl E 735-741  
 Stavem K 772-777  
 Stebbings AM 1234-1240  
 Steffensen F 119-127  
 Stolarek R 800-805  
 Stoller JK (CR) 1241-1251  
 Stout R 369-372  
 Stradling JR 895-899  
 Stuart AM SB29  
 Suemasu K 214-220  
 Suga M 784-790  
 Sugiura Y 1038-1042  
 Sugiyama Y 1085-1091  
 Sullivan EJ (CR) 1241-1251  
 Sundblad B-M 139-144  
 Suwalski M 800-805  
 Suyama H 71-75  
 Svahn T 678-683  
 Svanborg E 569-572  
 Svedberg-Brandt S 145-149  
 swine dust exposure in healthy volunteers, airway reactivity and exhaled NO following 1065-1072  
 Sykes AP SB17, SB22, SB42  
 Taccola M 441-447  
 Taivainen A 678-683  
 Takabatake N 1215-1220  
 Takahara J 475-481, 875-880  
 Takahashi H 847-851  
 Takano K 71-75  
 Takano Y 784-790  
 Takeuchi T 875-880  
 Talamo S 128-134, 240-246  
 Tanaka H 935-942  
 Tanser SJ (CR) 1004-1006  
 Tashkin DP SD37  
 Taube C 1184-1191  
 Taylor DR 767-771  
 Taylor J 983-984  
 Taytard A 1047-1052  
 t-cell activation by organic dust *in vitro* 821-827  
 technetium <sup>99m</sup>Tc-DTPA clearance in the evaluation of pulmonary involvement in patients with diabetes mellitus 1053-1056  
 Teixeira AK 64-70  
 ten Thoren C 409-415  
 Teramoto S 847-851, 935-942  
 Terashita K 1215-1220  
 Thébault J-J 490-495  
 theophylline: potential inhibitory effect on oxidative stress in asthma and COPD 584-588  
 Thiagamoorthy S 1253  
 Thirstrup S 328-336, 519-528  
 Thwaites RMA 724-732  
 Todorov T (CR) 830-831  
 Tomita H 1038-1042  
 Tomoike H 155-160, 1215-1220  
 Tonnel AB SB29  
 Torén K 529-535  
 tracheostomy: influence of clinical history on airways bacterial colonization 436-440  
 Trakada G 992-996  
 Tramaglino LM 1171-1176  
 Traserra J 428-431  
 trends in bronchial hyperresponsiveness, respiratory symptoms and lung function among adults in Germany 668-677  
 trimellitic anhydride immunological lung disease and human leucocyte antigens 964-970  
 Tsang KW 756-759, 943-945  
 Tsourapis S 992-996  
 Tsukagoshi H 584-588  
 Tsukino M 841-846  
 tuberculosis and acquired immunodeficiency syndrome, preferential recruitment of phagocytes into the lung 64-70  
 tuberculosis preventive therapy: perspective from a multi-ethnic community 648-653  
 Tukiainen H 678-683  
 Tunon-de-Lara JM 1047-1052  
 Turbohaler: characterization of the inspiratory manoeuvre when asthmatics inhale pre- and post-counselling in a community pharmacy 501-504  
 Turbuhaler<sup>®</sup> and Diskus<sup>®</sup>, equivalent therapeutic ratio of salbutamol given by 574-577  
   : budesonide, comparison with HFA-BDP Autohaler<sup>®</sup> in control of patients with mild to moderately severe asthma SD27  
   : formoterol given by (Oxis<sup>®</sup>) showed as rapid an onset of action as salbutamol given by a pMDI 607-611

- :salbutamol via, salbutamol via Easyhaler<sup>®</sup> is at least as effective in the treatment of histamine-induced bronchoconstriction 1097-1102
- :with formoterol gave better protection than terbutaline against repeated exercise challenge 661-667
- Turcotte H 288-294
- Türköz Y 432-435
- Tylén U 38-43
- Uçan ES 891-894
- Uçgun I 536-541
- Uchida Y 542-548
- Ueda M 385-390
- Ueda R 1038-1042
- Ueda Y 475-481
- Ugurman F 432-435
- Underwood D (L) 181
- unexplained respiratory symptoms, frequency dependence of compliance in evaluation of patients 221-227
- Vagaggini B 441-447, 1073-1076
- Valente S 397-403
- van der Ploeg 806-814
- van Rens MThM 404-405
- Van Suylen RJ 815-820
- Vatn M 868-874
- Velicitat P 490-495
- Vence P SF9
- Venge P 564-568
- venous access devices, totally implantable, experience in adults with cystic fibrosis over a 13-year period 1161-1164
- Vernejoux JM 1047-1052
- Viegi G 194-204
- Vieira MAMS 64-70
- Viskum K 373-377
- Visual Analogue Scale 8, effectiveness in measuring health-related quality of life for COPD patients 1192-1199
- Vitalograph-R bellows spirometer, temperature of volumes measured not necessary (L) 917
- Vives M 505-510
- von Berg A 661-667
- von Hertzen L 356-363
- Wadsworth J 422-427, 954-963
- Walker L 2-9
- Walters EH SF26
- Wang C-H 654-660
- Ward MM 1123-1129
- Warner JH 1029-1037
- Water-pipe smoking and pulmonary functions 891-894
- Watson A 1103-1108
- Wauer RR 378-384
- Weber H-H SB17
- Wedzicha JA 589-598
- Weiner M 161-165
- Weiner P 161-165
- Weling-Scheepers C 859-867
- Wencker M 1177-1183, SC16
- Wennlund A 1221-1228
- Werneck-Barroso E 64-70
- Westbrook J 112-118
- Westermann CJJ 404-405
- White RJ (CR) 176
- Wichmann HE 668-677
- Wiest GH 364-368
- Williams D 97-105
- Wilson L 204-213
- Wilson R 791-799
- Winter RJD 900-908
- Withers NJ 391-396
- Wong BCY 756-759
- Woodhead MA 422-427
- Woodhouse R SB3-7
- Woolcock AJ 715-723
- Worth H SD27
- Wouters EFM 815-820, 859-867
- Wu A 756-759
- Wyatt HA 106-111
- Xaubet A 345-349, 428-431
- Xu SY 564-568
- Yamada Y 1038-1042
- Yamamoto H 87-90
- Yang XX 44-50
- Yarnold PR 964-970
- Yasumura S 1215-1220
- Yildirim Z 432-435
- Yilmaz Turay Ü 432-435
- Yokomura I 385-390
- Yu C-T 654-660
- Yuki H 1215-1220
- Zaccaria S 436-440
- zafirlukast, effect on bronchial hyper-responsiveness compared with fluticasone propionate 112-118
- Zamarrón C 835-840
- zanamivir, effects on pulmonary function and airway responsiveness in asthmatics 166-173
- Zanen P (L) 180
- Zeiss CR 964-970
- Zetterström O 1097-1102
- Zheng L 756-759
- Zieba M 800-805
- Ziviani L SB10-17
- Zompatori M 702-708





